These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30605443)

  • 1. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
    Chen L; Yang G; Dong H
    Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
    BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
    Ono M; Oba T; Shibata T; Ito KI
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3211-3224. PubMed ID: 34244855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
    Du L; Li X; Zhen L; Chen W; Mu L; Zhang Y; Song A
    Mol Med Rep; 2018 May; 17(5):7163-7169. PubMed ID: 29568883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Sun H; Yin M; Qian W; Yin H
    Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
    Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
    Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
    Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
    Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Petrossian K; Nguyen D; Lo C; Kanaya N; Somlo G; Cui YX; Huang CS; Chen S
    Breast Cancer Res Treat; 2018 Aug; 170(3):499-506. PubMed ID: 29623577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.